Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
16 sept. 2024 09h00 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
05 sept. 2024 09h00 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients...
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
04 sept. 2024 16h15 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
North America Cancer Biopsy Market Research Report 2024
28 août 2024 11h10 HE
|
Research and Markets
Dublin, Aug. 28, 2024 (GLOBE NEWSWIRE) -- The "North America Cancer Biopsy Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
North America $3.62 Bn Nuclear Medicine Market by Country, Competition, Forecast & Opportunities, 2019-2023 & 2024-2029
26 août 2024 10h52 HE
|
Research and Markets
Dublin, Aug. 26, 2024 (GLOBE NEWSWIRE) -- The "North America Nuclear Medicine Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
Radiotherapy, Radiopharmaceuticals and Nuclear Medicine Global Markets Research 2021-2029: Increasing Demand in Developing Regions, Applications Beyond Oncology, Theranostics Gaining Traction
21 août 2024 06h57 HE
|
Research and Markets
Dublin, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The "Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market...
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
14 août 2024 16h10 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Bladder Cancer Therapeutics Market is Likely to Reach USD 456.3 million by 2034 at a CAGR of 4.8% | Report Analysis by Transparency Market Research Inc.
09 août 2024 10h18 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Aug. 09, 2024 (GLOBE NEWSWIRE) -- The global bladder cancer therapeutics market(방광암 치료제 시장) stood at US$ 271.4 million in...
Radiation Detection, Monitoring & Safety - Global Market Outlook 2024-2029 by Product, Composition, Material, Application and Region
08 août 2024 04h39 HE
|
Research and Markets
Dublin, Aug. 08, 2024 (GLOBE NEWSWIRE) -- The "Global Radiation Detection, Monitoring & Safety Market by Product (Dosimeters, Monitors), Composition (Gas-Filled Detectors, Scintillators),...
Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
19 juil. 2024 09h00 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...